Nexalin's deep brain stimulation add-on therapy alleviates depression [Yahoo! Finance]
Nexalin Technology, Inc. (NXL)
Company Research
Source: Yahoo! Finance
The results were published in the Brain Stimulation journal and showed that the neurostimulation device when used in combination with a selective serotonin reuptake inhibitor (SSRI) - AbbVie's Lexapro (escitalopram) - is more effective compared to medication alone. SSRIs are currently the standard of care for MDD. The double-blind, randomised, sham-controlled trial enrolled 66 participants with MDD. The participants received 20 40-minute sessions of either Nexalin's non-invasive Deep Intracranial Frequency Stimulation (DIFS) technology or sham stimulation. All participants also received Lexapro throughout the four weeks. At week four, 66.7% of the participants in the active treatment responded to therapy, compared to 33.3% of the participants in the sham group. There were significant differences found in the mean reduction of the Hamilton Depression Rating Scale (HAMD-17) scores at week four, the trial's primary endpoint. “While we have previously demonstrated powerful treatmen
Show less
Read more
Impact Snapshot
Event Time:
NXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NXL alerts
High impacting Nexalin Technology, Inc. news events
Weekly update
A roundup of the hottest topics
NXL
News
- Nexalin Technology Announces Pricing of $5.2 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- Nexalin Technology Announces Pricing of $5.2 Million Public OfferingGlobeNewswire
- Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal [Yahoo! Finance]Yahoo! Finance
- Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific JournalGlobeNewswire
- Nexalin secures US patent for Alzheimer's deep-brain stimulation device [Yahoo! Finance]Yahoo! Finance
NXL
Sec Filings
- 6/28/24 - Form 8-K
- 6/28/24 - Form EFFECT
- 6/26/24 - Form S-1/A
- NXL's page on the SEC website